RRx-001 and Pathologic Remodeling: Dr. Pedro Cabrales Presents at the American Physiology Summit

by EpicentRx | Apr 28, 2023 | Blog

Chances are, if you own a television—or if you’ve been to the dentist recently—you’ve come across trendy and formulaic home remodeling shows like Fixer Upper, Grand Designs, Trading Spaces, Flip or Flop, Home Town, Property Brothers, Love It or List It, or House...

Breaking News: New Test to Diagnose Pre-symptomatic Parkinson’s Disease

by EpicentRx | Apr 17, 2023 | Blog

Ever since Parkinson’s Disease (PD) was officially described as a neurological syndrome by the English surgeon, geologist, and paleontologist, Dr. James Parkinson, over two centuries ago in an 1817 treatise entitled, “An Essay on the Shaking Palsy”, the only way to...

The AdAPT-001 “Whichdunit”

by EpicentRx | Apr 10, 2023 | Blog

Ok, so everyone likes a good “whodunit”. This is the genre of classic “pure puzzle” mysteries where the dramatic final “reveal” of the culprit, the person “who did it”, takes place at the end or denouement after a long suspense-filled buildup, with plot twists and red...

RRx-001 and FDA Fast Track

by EpicentRx | Apr 4, 2023 | Blog

The big news at EpicentRx last week is that its lead small molecule, RRx-001, received Fast Track designation for the prevention/amelioration of severe oral mucositis (SOM). What is oral mucositis, how does RRx-001 prevent/ameliorate it, and why is this big news?...

EpicentRx Receives Fast Track Designation from the U.S. FDA for Lead Asset, RRx-001, to Prevent/Attenuate Chemotherapy and Radiation Treatment Induced Severe Oral Mucositis

by EpicentRx | Mar 29, 2023 | 2023, Press Releases

FDA also accepts company’s Investigational New Drug (IND) application to initiate a follow-on phase 2b clinical trial, called KEVLARx TORREY PINES, CA, March 29, 2023 — EpicentRx, Inc. (“EpicentRx”), announced today that the U.S. Food and Drug Administration...